Beryl Drugs Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Beryl Drugs has been growing earnings at an average annual rate of 20.2%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 21.4% per year. Beryl Drugs's return on equity is 6.8%, and it has net margins of 2.4%.
Belangrijke informatie
20.2%
Groei van de winst
20.2%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 17.5% |
Inkomstengroei | 21.4% |
Rendement op eigen vermogen | 6.8% |
Nettomarge | 2.4% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Beryl Drugs geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 249 | 6 | 20 | 0 |
31 Mar 24 | 267 | 8 | 20 | 0 |
31 Dec 23 | 299 | 12 | 19 | 0 |
30 Sep 23 | 304 | 10 | 19 | 0 |
30 Jun 23 | 301 | 11 | 18 | 0 |
31 Mar 23 | 269 | 8 | 17 | 0 |
31 Dec 22 | 242 | 2 | 15 | 0 |
30 Sep 22 | 193 | 0 | 15 | 0 |
30 Jun 22 | 149 | -8 | 13 | 0 |
31 Mar 22 | 146 | -7 | 13 | 0 |
31 Dec 21 | 172 | -1 | 14 | 0 |
30 Sep 21 | 161 | -1 | 13 | 0 |
30 Jun 21 | 160 | 8 | 12 | 0 |
31 Mar 21 | 141 | 2 | 12 | 0 |
31 Dec 20 | 111 | -4 | 11 | 0 |
30 Sep 20 | 113 | -2 | 11 | 0 |
30 Jun 20 | 113 | -5 | 10 | 0 |
31 Mar 20 | 128 | 0 | 10 | 0 |
31 Dec 19 | 120 | 7 | 9 | 0 |
30 Sep 19 | 128 | 8 | 9 | 0 |
30 Jun 19 | 130 | 7 | 9 | 0 |
31 Mar 19 | 130 | 6 | 9 | 0 |
31 Dec 18 | 143 | 8 | 9 | 0 |
30 Sep 18 | 148 | 7 | 9 | 0 |
30 Jun 18 | 145 | 11 | 8 | 0 |
31 Mar 18 | 152 | 10 | 8 | 0 |
31 Dec 17 | 141 | 7 | 7 | 0 |
30 Sep 17 | 130 | 5 | 8 | 0 |
30 Jun 17 | 128 | 1 | 9 | 0 |
31 Mar 17 | 113 | -4 | 10 | 0 |
31 Dec 16 | 102 | 0 | 11 | 0 |
30 Sep 16 | 105 | 1 | 12 | 0 |
30 Jun 16 | 115 | 2 | 13 | 0 |
31 Mar 16 | 131 | 2 | 12 | 0 |
31 Dec 15 | 150 | 1 | 14 | 0 |
30 Sep 15 | 150 | 1 | 22 | 0 |
30 Jun 15 | 146 | 3 | 40 | 0 |
31 Mar 15 | 133 | 1 | 12 | 0 |
31 Dec 14 | 121 | 1 | 24 | 0 |
30 Sep 14 | 130 | 2 | 22 | 0 |
30 Jun 14 | 137 | 2 | 22 | 0 |
31 Mar 14 | 146 | 3 | 21 | 0 |
31 Dec 13 | 135 | 2 | 17 | 0 |
Kwaliteitswinsten: 524606 has high quality earnings.
Groeiende winstmarge: 524606's current net profit margins (2.4%) are lower than last year (3.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 524606's earnings have grown significantly by 20.2% per year over the past 5 years.
Versnelling van de groei: 524606's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 524606 had negative earnings growth (-43.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.1%).
Rendement op eigen vermogen
Hoge ROE: 524606's Return on Equity (6.8%) is considered low.